Long-term neurotoxic brain damage in ecstasy (MDMA) users. A review of the literature;Neurotoxische langzeitschäden bei ecstasy (MDMA)-konsumenten: Überblick über den aktuellen wissensstand

Nervenarzt

Volumn 73, Issue 5, 2002, Pages 405-421

  Gouzoulis Mayfrank, E ^a   Daumann, J ^a   Sass H ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Ecstasy; MDMA; Memory; Neurotoxicity; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; SEROTONIN;

AUTONOMIC DYSFUNCTION; BRAIN FUNCTION; BRAIN INJURY; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; MEMORY; MENTAL DISEASE; NEUROENDOCRINE DISEASE; NEUROTOXICITY; REVIEW; SEROTONINERGIC SYSTEM;

EID: 0036934781     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-001-1243-6     Document Type: Review

References (98)

1. Allen RP, McCann UD, Ricaurte GA (1993) Persistent effects of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") on human sleep. Sleep 16: 560-564
2. Aguirre N, Barrionuevo M, Ramirez MJ, Del Rio J, Lasheras B (1999) α-lipoic acid prevents 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity. Neuroreport 10: 3675-3680
3. Andresen B, Thomasius R, Anders L, Moritz S, Petersen KU, Luck S (2000) Neuropsychologische Ergebnisse. In: Thomasius R (ed) Ecstasy Eine Studie zu gesundheitlichen und psychosozialen Folgen des Missbrauchs. Wissenschaftliche Verlagsgesellschaft, Stuttgart, pp 171-187
4. Baumgarten HG, Grozdanovic Z (1997) Anatomy of central serotonergic projection systems. In: Baumgarten HG, Göthert M (eds) Serotonergic neurons and 5-HT receptors. The CNS Handbook of experimental pharmacology, Vol 129. Springer, Berlin Heidelberg New York, pp 41-89
5. Battaglia G, Yeh SY, De Souza EB (1988) MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 29: 269-274
6. Bhattachary S, Powell JH (2001) Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or "ecstasy": evidence for cognitive impairment. Psychol Med 31: 647-658
7. Bolla KI, McCann DU, Ricaurte GA (1998) Memory impairment in abstinent MDMA (, Ecstasy") users. Neurology 51: 1532-1537
8. Buchert R, Obrocki J, Thomasius R et al. (2001) Long-term effects of "ecstasy" abuse on the human brain studied by FDG PET. Nuclear Med Commun 22: 889-897
9. Buck U, Petersen KU, Andresen B, Adamaszek M (2000) Ergebnisse der Elektroenzephalographie. In: Thomasius R (ed) Ecstasy - Eine Studie zu gesundheitlichen und psychosozialen Folgen des Missbrauchs. Wissenschaftliche Verlagsgesellschaft, Stuttgart, pp 208-210
10. Carrillo-de-la-Pena MT (1992) ERP augmenting/reducing and sensation seeking: a critical review. IntJ Psychophysiol 12: 211-220
11. Chang L, Ernst T, Grob CS, Poland RE (1999) Cerebral (1)H MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) users. J Magn Reson Imaging 10: S21-S26
12. Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, Poland RE (2000) Effect of ecstasy (3,4-methylenedioxymethamphetamine (MDMA) on cerebral blood flow: a co-registered SPECT and MRI study. Psychiatry Res Neuroimaging 98: 15-28
13. Coccaro EF, Siever LI, Klar HM et al. (1989) Serotonergic studies in patients with affective and personality disorders. Arch Gen Psychiatry 46: 587-599
14. Cohen RS (1995) Subjective reports on the effects of the MDMA (ecstasy) experience in humans. Prog Neuropsychopharmacol Biol Psychiatry 19: 1137-1143
15. Colado MI, O'Shea E, Granados R, Murray TK, Green AR (1997) In vivo evidence for free radical involvement in the degeneration of rat brain 5-HAT following administration of MDMA ("ecstasy") and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol 121: 889-900
16. Colado MI, Granados R, O'Shea E, Esteban B, Green AR (1998) Role of hyperthermia in the protective action of clomethiazole against MDMA-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR. Br J Pharmacol 124: 479-484
17. Cooper GA, Allen DL, Scott KS, Oliver JS, Ditton J, Smith ID (2000) Hair analysis: self-reported use of "speed" and "ecstasy" compared with laboratory findings. J Forensic Sci 45: 400-406
18. Croft RJ, Mackay AJ, Mills ATD, Gruzelier JGH (2001) The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology 153: 373-379
19. Curran VH (2000) Is MDMA (Ecstasy) neurotoxic in humans? An overwiew of evidence and of methodological problems in research. Neuropsychobiology 42: 34-41
20. Curran HV, Travill RA (1997) Mood and cognitive effects of ±3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): week-end "high" followed by mid-week low. Addiction: 821-831
21. Dafters RI, Duffy F, O'Donnell PJ, Bouquet C (1999) Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence. Psychopharmacology 145: 82-90
22. Daumann J, Pelz S, Becker S, Tuchtenhagen F, Gouzoulis-Mayfrank E (2001) Psychological profile of recreational ecstasy (MDMA) users and significance of concomitant cannabis use. Hum Psychopharmacol 8, online Publikation 12/12/01
23. Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G (1995) Reorganization of ascending 5-HAT axon projections in animals previously exposed to the recreational drug 3,4-methyl-enedioxymethamphetamine (MDMA, Ecstasy). J Neurosci 15: 5476-5485
24. Flüsmeier U, Rakete G (1999) Konsummuster und psychosoziale Effekte des Konsums. In: Thomasius R (ed) Ecstasy - Wirkungen, Risiken, Interventionen. Enke, Stuttgart, pp 83-95
25. Frederick DL, Paule MG (1997) Effects of MDMA on complex brain function in laboratory animals. Neurosci Biobehav Rev 21: 67-78
26. Gamma A, Buck A, Berthold Th, Vollenweider FX (2001) No difference in brain activation during cognitive performance between ecstasy (3,4-Methylenedioxymethamphetamine) users and control subjects. J Clin Psychopharmacol 21: 66-71
27. Gamma A, Frei E, Lehmann D, Pascua-Marqui RD, Hell D, Vollenweider FX (2000) Mood state and brain electric activity in Ecstasy users. Neuroreport 11: 157-162
28. Gerra G, Zaimovic A, Giucastro G et al. (1998) Serotonergic function after 3,4-methyl-enedioxymethamphetamine (Ecstasy) in humans. Int Clin Psychopharmacol 13: 1-9
29. Gerra G, Zaimovic A, Ferri M et al. (2000) Long-lasting effects of 3,4-methylenedioxymethamphetamine (ecstasy) on serotonin function in humans. Biol Psychiatry 47: 127-136
30. Gouzoulis-Mayfrank E (1999) Wirkungen und Risiken des Ecstasy-Konsums: Psychotrope und neurobiologische Wirkungen. In: Thomasius R (ed) Ecstasy-Wirkungen, Risiken, Interventionen. Ein Leitfaden für Klinik und Praxis. Enke, Stuttgart, pp 39-52
31. Gouzoulis-Mayfrank E, Hermle L, Kovar K-A, Sass H (1996) Die Entaktogene: "Ecstasy" (MDMA), "Eve" (MDE) und andere ring-substituierte Methamphetaminderivate. Eine neue Stoffklasse unter den illegalen Designer-Drogen? Nervenarzt 67: 369-380
32. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E et al. (1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methyl-enedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology 142: 41-50
33. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F et al. (2000) Impaired cognitive performance in drug-free recreational ecstasy (MDMA) users. J Neurol Neurosurg Psychiatry 68: 719-725
34. Gouzoulis-Mayfrank E, Becker S, Pelz S, Tuchtenhagen F, Daumann J (2002) Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: is it ecstasy or cannabis? Biol Psychiatry
35. Green AR, Cross AJ, Goodwin GM (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology 119: 246-260
36. Hatzidimitriou G, Mc Cann DU, Ricaurte GA (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with 3,4-methylenedioxymethampheta mine seven years previously: factors influencing abnormal recovery. J Neurosci 19: 5096-5107
37. Heal DJ, Philpot J, Molyneux SG, Merz A (1985) Intracerebroventricular administration of 5,7-dihydrotryptamine to mice increases both head-twitch response and the number of cortical 5-HT2 receptors. Neuropharmacology 24: 1201-1203
38. Hegadoren KM, Baker GB, Bourin M (1999) 3,4-methylenedioxy analogues of amphetamine: Defining the risks to humans. Neurosci Biobehav Rev 23: 539-553
39. Hegerl U, Juckel G (1993) Intensity dependence of auditory evoked potentials as indicator of central serotonergic neurotransmission - a new hypothesis. Biol Psychiatry 33: 173-187
40. Hegerl U, Juckel G, Möller H-J (1996) Ereigniskorrelierte Hirnpotentiale als Indikatoren neurochemischer Dysfunktionen bei psychiatrischen Patienten. Nervenarzt 67: 360-368
41. Heinz A, Jones DW (2000) Serotonin transporters in ecstasy users. Br J Psychiatry 17: 193-195
42. Herpertz S, Steinmeyer SM, Marx D, Oidtmann A, Saß H (1995) The significance of aggression and impulsivity for self-mutilative behavior. Pharmacopsychiatry 28S: 64-72
43. Hüther G, Rüther E (2000) Das serotonerge System. UNI-MED, Bremen
44. Jacobs BJ, Azmitia EC (1992) Structure and function of the brain serotonin system, Physiol Rev 72: 165-229
45. Jimerson DC, Wolfe BE, Metzger ED, Finkelstein DM, Cooper TB, Levine JM (1997) Decreased serotonin function in bulimia nervosa. Arch Gen Psychiatry 54: 529-534
46. Jones BE (1989) Basic mechanisms of sleep. In: Kryger MH, Roth T, Dement WC (eds) Principles and practice of sleep medicine. Saunders, Philadelphia, pp 121-141
47. Juckel G, Schmidt LG, Rommelspacher H, Hegerl U (1995) The tridimensional personality questionnaire and the intensity dependence of auditory evoked dipole source activity. Biol Psychiatry 37: 311-317
48. Klugman A, Gruzelier J (1998) The neuropsychophysiology of MDMA. Int J Psychophysiol 30: 71 (Abstr)
49. Klugman A, Hardy S, Baldeweg T, Gruzelier J (1999) Toxic effect of MDMA on brain serotonin neurons. Lancet 353: 1268 (Correspondence)
50. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR (1992) Chronic 3,4-Methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 18: 331-341
51. Lewis DA, Campbell MJ, Foote SL (1986) The momoaminergic innervation of primate neocortex. Hum Neurobiol 5: 181-188
52. Marston HM, Reid ME, Lawrence JA, Olverman HJ, Butcher SP (1999) Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat. Psychopharmacology 144: 67-76
53. Mc Cann DU, Ridenour A, Shaham Y, Ricaurte GA (1994) Serotonin neurotoxicity after 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy): A controlled study in humans. Neuropsychopharmacology 10: 129-138
54. McCann DU, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352 (9138): 1433-1437
55. McCann DU, Eligulashvili V, Mertl M, Murphy DL, Ricaurte GA (1999) Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology 147: 56-65
56. McCann DU, Mertl M, Eligulashvili V, Ricaurte GA (1999) Cognitive performance in 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) users: a controlled study. Psychopharmacology 143: 417-425
57. McCann DU, Eligulashvili V, Ricaurte GA (2000) 3,4-methylenedioxymethamphetamine (Ecstasy)-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 42: 11-16
58. Morgan MJ (1998) Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 19: 252-264
59. Morgan MJ (1999) Memory deficits associated with recreational use of, ecstasy" (MDMA). Psychopharmacology 141: 30-36
60. New AS, Trestman RL, Mitropoulou V, Benishay DS, Coccaro E, Silverman J, Siever LJ (1997) Serotonergic function and self-injurious behavior in personality disorder patients. Psychiatry Res 69: 17-26
61. Obrocki J, Buchert R, Väterlein O, Thomasius R, Beyer W, Schiemann T (1999) Ecstasy - longterm effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry 175: 186-188
62. Park SB, Coull JT, McShane RH, Young AH, Sahakian BJ, Robbins TW, Cowen PJ (1994) Tryptophan depletion in normal volunteers produces selective impairments of learning and memory. Neuropharmacology 33: 575-588
63. Parrott AC (2000) Human research on MDMA (3,4-methylenedioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology 42: 17-24
64. Parrott AC, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology 139: 261-268
65. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K (1998) Cognitive performance in recreational users of MDMA ("ecstasy"): evidence for memory deficits. J Psychopharmacol 12: 79-83
66. Parrott AC, Sisk E, Turner JJ (2000) Psychobiological problems in heavy "ecstasy" (MDMA) polydrug users. Drug Alcohol Depend 60: 105-110
67. Parsey RV, Kegeles LS, Hwang DR et al. (2000) In vivo quantification of brain serotonin transporters in humans using [11C]McN5652. J Nucl Med 41: 1465-1477
68. Peroutka SJ, Pascoe N, Faull KF (1987) Monoamine metabolites in the cerebrocpinal fluid of recreational users of MDMA. Res Comm Substance Abuse 8: 125-138
69. Price LH, Ricaurte GA, Krystal JH, Heninger GR (1989) Neuroendocrine and mood responses to intravenous L-tryptophan in MDMA users. Arch Gen Psychiatry 46: 20-22
70. Reneman L, Booij J, Schmand B, van den Brink W, Gunning B (2000) Memory disturbances in "ecstasy" users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology 148: 322-324
71. Reneman L, Habraken JBA, Majoie CBL, Booij J, den Heeren GJ (2000) MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings. AJNR Am J Neuroradiol 21: 1001-1007
72. Reneman L, Majoie CBL, Habraken JBA, den Heeren GJ (2001): Effects of ecstasy (MDMA) on the brain in abstinent users: initial observations with diffusion and perfusion MR imaging. Radiology 220: 611-617
73. Reneman L, Majoie CBL, Schmand B, van den Brink W, den Heeren GJ (2001) Prefrontal N-acetylaspartate is strongly associated with memory performance in abstinent ecstasy users: preliminary report. Biol Psychiatry 50: 550-554
74. Ricaurte GA, Finnegan KT, Irwin I, Langston W (1990) Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: Preliminary obserations. Ann NY Acad Sci 600: 699-710
75. Ricaurte GA, Martello AL, Katz JL, Martello MB (1992) Lasting effects of MDMA on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 261: 616-622
76. Ricaurte GA, Yuan J, McCann DU (2000) 3,4-methylenedioxymethamphetamine (Ecstasy)-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42: 5-10
77. Rodgers J (2001) Cognitive performance amongst recreational users of "ecstasy". Psychopharmacology 151: 19-24
78. Rothe M, Pragst F, Spiegel K, Harrach T, Fischer K, Kunkel J (1997) Hair concentrations and self-reported abuse history of 20 amphetamine and ecstasy users. Forensic Sci Int 89: 111-128
79. Scheffel U, Lever JR, Stathis M, Ricaurte GA (1992) Repeated administration of MDMA causes transient down-regulation of serotonin 5-HT2 receptors. Neuropharmacology 31: 881-893
80. Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R (1998) MDMA (ecstasy) consumption in the context of poly-drug abuse: A report on 150 patients. Drug Alcohol Depend 52: 85-90
81. Schroder S, Bornhövd-Braeuer K, Stürenburg HJ, Rosenkranz M, Thomasius R (2000) Neurologische Ergebnisse. In: Thomasius R (ed) Ecstasy - Eine Studie zu gesundheitlichen und psychosozialen Folgen des Missbrauchs. Wissenschaftliche Verlagsgesellschaft, Stuttgart, pp 188-195
82. Schuster P, Wittchen H-U (1996) Ecstasy- und Halluzinogengebrauch bei Jugendlichen Gibt es eine Zunahme? Verhaltenstherapie 6: 222-232
83. Seiden LS, Sabol KE (1996) Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res Monogr 163: 251-276
84. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ("ecstasy") users. Br J Psychiatry 175: 63-69
85. Sirvio J, Riekkinen P, Jakala P, Riekkinen PJ (1994) Experimental studies on the role of serotonin in cognition. Prog Neurobiol 43: 363-379
86. Spatt J, Glawar B, Mamioli B (1997) A pure amnesic syndrome after MDMA (ecstasy) ingestion. J Neurol Neurosurg Psychiatry 62: 418-428
87. Speck A, Reimers S (1999) Forschungsinitiative zur zielgerichteten Ecstasy-Prävention - Repräsentativbefragung zum Drogenkonsum schleswig-holsteinischer Schülerlnnen. Studie im Auftrag des Ministeriums für Arbeit, Gesundheit und Soziales des Landes Schleswig-Holstein, durchgeführt von der Landesstelle gegen die Suchtgefahren für Schleswig-Holstein, zu beziehen über das Ministerium für Arbeit, Gesundheit und Soziales des Landes Schleswig-Holstein
88. Sprague JE, Everman SL, Nichols DE (1998) An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 19: 427-442
89. Theune M, Esser W, Druschky K-F, Interschick E, Patscheke H (2000) Grand-mal-Serie nach Ecstasy-Einnahme. Nervenarzt 70: 1094-1097
90. Thomasius R (1999) Psychiatrische, neurologische und internistische Komplikationen und Folgewirkungen. In: Thomasius R (ed) Ecstasy Wirkungen, Risiken, Interventionen. Ein Leitfaden für Klinik und Praxis. Enke, Stuttgart, pp 61-69
91. Thomasius R, Schmolke M, Kraus D (1997) MDMA (Ecstasy) Konsum - ein Überblick zu psychiatrischen und medizinischen Folgen. Fortschr Neurol Psychiatr 65: 49-61
92. Thomasius R, Konietzky A, Petersen KU, Wuchner M (2000) Psychiatrische Ergebnisse. In: Thomasius R (ed) Ecstasy - Eine Studie zu gesundheitlichen und psychosozialen Folgen des Mißbrauchs. Wissenschaftliche Verlagsgesellschaft, Stuttgart, pp 110-135
93. Tossmann HP (1997) Ecstasy-Konsummuster, Konsumkontexte und Komplikationen. Ergebnisse der Ecstasy-Infoline. Sucht 43: 121-129
94. Tuchtenhagen F, Daumann J, Norra C et al. (2000) High intensity dependence of auditory evoked N1/P2 dipole source activity in abstinent ecstasy (MDMA) users. Neuropsychopharmacology 21: 608-617
95. Verkes RJ, Gijsman HJ, Pieters RC et al. (2001) Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 153: 196-202
96. Von Schrenck T, Hannesen C, Bandilla (2000) Ergebnisse der Inneren Medizin. In: Thomasius R (ed) Ecstasy - Eine Studie zu gesundheitlichen und psychosozialen Folgen des Missbrauchs. Wissenschaftliche Verlagsgesellschaft, Stuttgart, pp 224-232
97. Wareing M, Fisk JE, Murphy PN (2000) Working memory deficits in current and previous users of MDMA ("ecstasy"). Br J Psychol 91: 181-188
98. Zakzanis KK, Young DA (2001) Memory impairment in abstinent MDMA ("ecstasy") users: A longitudinal investigation. Neurology 56: 966-969